Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes ...

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.